Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMY-922 for Refractory Autoimmune Disease
NCT07729995Phase 1Not yet recruiting
- Sponsor
- Luminary Therapeutics
- Start
- Oct 2026
- Primary completion
- Mar 2030
- Countries
- 1
01
Overview
Phase 1, open-label trial of LMY-922 in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), dermatomyositis (DM) and 1 more (3 arms), sponsored by Luminary Therapeutics. Primary endpoints: Incidence and Severity of Treatment-Emergent Adverse Events at 24 Months and Dose Limiting Toxicities at 24 Months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
LMY-922
03
Conditions
rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)dermatomyositis (DM)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07729995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07729995.